secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seer, Inc. (SEER)
CIK:        0001726445
Form:       8-K
Filed at:   2021-11-09T23:59:59+00:00
Accession:  0001628280-21-022540
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seer Q3 2021 revenue $2.2M, net loss $18.4M; on track for broad release in early 2022
--------------------------------------------------------------------------------

- Revenue $2.2M vs $72K in Q3 2020; product-related revenue $1.6M including $787K from related party.
- Gross margin 54%; operating expenses $19.6M (up from $8.5M) due to higher compensation and public company costs.
- Net loss $18.4M vs $8.2M; cash and investments $506.6M as of Sept 30, 2021.
- Added new Limited Release customers; on track for high single-digit total; broad release expected early 2022.
- Customer studies: Oregon Health (prostate cancer, 500-1000 samples), Broad Institute (proteome depth), Sanford Burnham (TMT), Protein Metrics (glycoproteome).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1726445/000162828021022540/0001628280-21-022540-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1726445/000162828021022540/seer-20211109.htm
  HTML page:      https://secwatch.observer/filing/0001628280-21-022540

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer